Sign inJoin waitlistJoin the waitlist

Geoffrey Uy

WashU) · Alvin J. Siteman Cancer Center

Credentials: · · · · · ·

History

Alvin J. Siteman Cancer Center
Present

Hematology and Medical Oncology
2004–2007
Internal Medicine
2001–2004
Washington University School of Medicine
1997–2001

Research

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
New England Journal of Medicine · 2018 · 1,234 citations
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid…
Journal of Clinical Oncology · 2018 · 802 citations
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
New England Journal of Medicine · 2016 · 716 citations

John DiPersio
70 papers
PW
Peter Westervelt
57 papers
Ravi Vij
43 papers
Camille Abboud
42 papers
Keith Stockerl-Goldstein
40 papers
Amanda Cashen
39 papers
Richard Stone
36 papers
Mark Schroeder
30 papers
Bayard Powell
23 papers
JK
Jonathan Kolitz
23 papers
Meagan Jacoby
23 papers
Wendy Stock
22 papers

Grants

Clinician Scientist in Leukemia
National Cancer Institute · R50
Contact PI · $531.1K · Washington University
2023–2028
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $91.8K · Washington University
2001–2027
Specialized Program of Research Excellence (SPORE) in Leukemia
National Cancer Institute · P50
Project lead · $3.4M · Washington University
2013–2024
Targeting Leukemia Stromal Interactions in AML
National Cancer Institute · K23
Contact PI · $793.3K · Washington University
2009–2015

Clinical trials

ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
Principal investigator · Not yet recruiting · Phase 1
Washington University School of Medicine
2026–2031
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Principal investigator · Suspended · Phase 1
Washington University School of Medicine
2023–2027
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Principal investigator · Active not recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2019–2026
BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Principal investigator · Terminated · Phase 2
Washington University School of Medicine
2016–2022